Insights

Gathering insights about Inotrem…

Similar companies to Inotrem

Inotrem Tech Stack

Inotrem uses 8 technology products and services including Twitter Emoji (Twemoji), Font Awesome, jQuery Migrate, and more. Explore Inotrem's tech stack below.

Twitter Emoji (Twemoji)
Font Scripts
Font Awesome
Font Scripts
jQuery Migrate
Javascript Libraries
jQuery UI
Javascript Libraries
jQuery
Javascript Libraries
Google Maps
Maps
YouTube
Video Players
Apache
Web Servers

Media & News

Inotrem SA is developing sTREM-1 assay on the Elecsys/COBAS platform on Jan 1st '17.
Inotrem is collaborating with Roche Diagnostics since 2017 to develop a sTREM-1 assay on the Elecsys/COBAS platform to identify patients that are both more at risk and more likely to benefit from nangibotide treatment.
Jan 07, 2024 | www.novumpr.nl
Inotrem SA launches antibody-based program.
In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases.
Nov 05, 2023 | finance.yahoo.com
Roche Diagnostics Ltd partnered with Inotrem SA on Sep 1st '20.
• In September 2020, Roche Diagnostics collaborated with Inotrem to develop the sTREM-1 test, a diagnostic solution for sepsis.
Jan 23, 2023 | www.digitaljournal.com
Inotrem SA launches ESSENTIAL.
Building on its deep scientific and medical understanding of the TREM-1 pathway, and with the strong support of the French government, Inotrem launched ESSENTIAL, its clinical trial to assess the efficacy of its drug lead candidate, nangibotide, for COVID-19 patients in the ICU.
Oct 24, 2022 | finance.yahoo.com
Inotrem SA hired Luke Beshar as Chairman of Board of Directors on May 25th '22.
Inotrem, an advanced clinical stage biotech company developing TREM- 1 targeting immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Luke Beshar as Chairman of its Board of Directors, effective May 25, 2022.
May 30, 2022 | www.fh-partners.com
Inotrem SA launches monoclonal antibody.
Inotrem is expanding its anti-TREM-1 work with a monoclonal antibody, yet to be tested in humans.
Mar 24, 2022 | endpts.com
Inotrem SA hired Laurent Vincens as Chief Technology Officer and Head of Manufacturing on Mar 17th '22.
Inotrem appoints Laurent Vincens as Chief Technology Officer and Head of Manufacturing.
Mar 16, 2022 | www.inotrem.com

Inotrem's Email Address Formats

Inotrem uses at least 1 format(s):

Inotrem Email Formats	Example	Percentage
FL@inotrem.com	JD@inotrem.com	90%
LastFirst@inotrem.com	DoeJohn@inotrem.com	5%
LF@inotrem.com	DJ@inotrem.com	3%
F.Last@inotrem.com	J.Doe@inotrem.com	2%

Frequently Asked Questions

Where is Inotrem's headquarters located?

Inotrem's main headquarters is located at 54, Rue de Ponthieu Paris, Île-de-France 75008 FR. The company has employees across 3 continents, including EuropeAsiaNorth America.

What is Inotrem's official website and social media links?

Inotrem's official website is inotrem.com and has social profiles on LinkedIn.

How much revenue does Inotrem generate?

As of August 2024, Inotrem's annual revenue reached $1.8M.

What is Inotrem's SIC code NAICS code?

Inotrem's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Inotrem have currently?

As of August 2024, Inotrem has approximately 33 employees across 3 continents, including EuropeAsiaNorth America. Key team members include Chief Executive Officer: S. Z.Chief Development Officer: M. S.Chief Operating Officer: M. K.. Explore Inotrem's employee directory with LeadIQ.

What industry does Inotrem belong to?

Inotrem operates in the Biotechnology Research industry.

What technology does Inotrem use?

Inotrem's tech stack includes Twitter Emoji (Twemoji)Font AwesomejQuery MigratejQuery UIjQueryGoogle MapsYouTubeApache.

What is Inotrem's email format?

Inotrem's email format typically follows the pattern of . Find more Inotrem email formats with LeadIQ.

When was Inotrem founded?

Inotrem was founded in 2013.

Inotrem

Biotechnology ResearchÎle-de-France, France11-50 Employees

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.

Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.

Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

Company Overview

Headquarters: 54, Rue de Ponthieu Paris, Île-de-France 75008 FR
Website: inotrem.com
SIC Code: 8733 - Noncommercial Research Organizations
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2013
Employees: 11-50

Media & News

Funding & Financials

$10M
Inotrem's revenue is in the range of $10M

Funding & Financials

$10M
Inotrem's revenue is in the range of $10M

Company Leadership

S. Z.
Chief Executive Officer
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. S.
Chief Development Officer
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. K.
Chief Operating Officer
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. G.
Executive Vice-President, Scientific And Medical Affairs
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
N. F.
Clinical Biomarkers, Translational Research And Biologistics Director
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

D. J.
Regulatory Affairs And Quality Assurance Director
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
E. V.
Research Alliances Director
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
S. D.
Finance, Controlling & Ipo Readiness Director
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. D. D. L. R.
Office Manager
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. N.
Lab Manager
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Inotrem and Millions of Other Companies
Sign up for full access to Inotrem information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Inotrem

Intact Vascular

PureTech Health

ProQR Therapeutics

Inotrem Tech Stack

Media & News

Inotrem SA is developing sTREM-1 assay on the Elecsys/COBAS platform on Jan 1st '17.

Inotrem SA launches antibody-based program.

Roche Diagnostics Ltd partnered with Inotrem SA on Sep 1st '20.

Inotrem SA launches ESSENTIAL.

Inotrem SA hired Luke Beshar as Chairman of Board of Directors on May 25th '22.

Inotrem SA launches monoclonal antibody.

Inotrem SA hired Laurent Vincens as Chief Technology Officer and Head of Manufacturing on Mar 17th '22.

Inotrem's Email Address Formats

Frequently Asked Questions

Where is Inotrem's headquarters located?

What is Inotrem's official website and social media links?

How much revenue does Inotrem generate?

What is Inotrem's SIC code NAICS code?

How many employees does Inotrem have currently?

What industry does Inotrem belong to?

What technology does Inotrem use?

What is Inotrem's email format?

When was Inotrem founded?

Inotrem

Company Overview

Media & News

Inotrem SA is developing sTREM-1 assay on the Elecsys/COBAS platform on Jan 1st '17.

Inotrem SA launches antibody-based program.

Roche Diagnostics Ltd partnered with Inotrem SA on Sep 1st '20.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?